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T estosteron e stim u la tes th e  exp ression  o f  IGF-I in  ce lls  and  
t issu es  th at in clu d e p rosta te , m uscle  and m uscle  sa te llite  
cells, and th e  u terus. H ere, the m olecu lar m echan ism s o f  th is  
effect o f  testo steron e  w ere  exp lored . T estosterone in creased  
IGF-I mRNA lev e ls  in  HepG2 and LNCaP cells  and stim u lated  
th e  a c tiv ity  o f  rep orter gen es con tro lled  by 1.6 kb o f th e  up­
stream  prom oter o f  th e  hum an IGF-I gen e. An androgen-re­
sp on sive  reg ion  th at w as located  b etw een  -1 3 2 0  and  -1 4 2 0  
b ases upstream  o f th e  first codon w as id en tified  by truncation  
stu d ies. The androgen-responsive reg ion  w as found  to con ta in  
tw o seq u en ces resem b lin g  know n androgen  recep tor  (AR)- 
bin d in g  s ite s  from  th e P em l gene. R eporter gen es incorpo­
ra tin g  th ese  seq u en ces w ere stron g ly  stim u lated  by andro-
TGF-F IS A PLURFPOTENT trophic factor for many cells and 
A  tissues. The major source of FGF-F in plasma is the liver, 
which releases this hormone in response to GH. FGF-F is also 
released by nonhepatic tissues, including muscle, muscle 
satellite cells, and cultured prostate cancer cells. Locally re­
leased FGF-F is believed to result in autocrine and paracrine 
control of tissue function. Several types of evidence suggest 
that FGF-F levels are also affected by testosterone. Testoster­
one administration has been reported to increase FGF-F levels 
in men (1). Levels of FGF-F mRNA are also increased by 
testosterone in skeletal muscle (2-4), muscle satellite cells (5), 
uterine tissue (6 ), and prostate stromal cells and cancer cell 
lines (7,8 ). The molecular mechanisms by which testosterone 
increases FGF-F expression in these cells and tissues are not 
known.
Testosterone acts by binding to and activating the andro­
gen receptor (AR), a member of the steroid hormone receptor 
subfamily of nuclear receptors that also includes receptors 
for glucocorticoids (GR), mineralocorticoids (MR) and pro­
gesterone (PR) (9,10). Steroid hormone receptors are ligand- 
activated transcription factors that contain an N-terminal 
transactivating domain, a highly conserved DNA-binding 
domain (DBD), and a C-terminal ligand-binding domain.
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gens. E ach o f  th e  androgen-resp onsive e lem en ts (AREs) 
bound recom b in ant AR-DNA-binding dom ain  in  gel-sh ift ex ­
p erim ents; b in d in g  w as greatly  en h an ced  by seq u en ces flank­
in g  th e  apparent A R -binding half-sites. T estosteron e in d u ced  
recru itm en t o f  AR to seq u en ces o f  genom ic DNA con ta in in g  
th ese  AREs. The tw o AREs w ere activated  5-fold m ore by AR  
than  g lu cocortico id  recep tor. C ollectively , th ese  fin d in gs in ­
d ica te  th e  p resen ce  o f  tw o AREs w ith in  th e  IGF-I upstream  
p rom oter th at act in  cis to  activate  IGF-I exp ression . T hese  
AREs seem  lik e ly  to con tribu te to the up-regu lation  o f  the  
IGF-I gen e in  p rosta te  tissu es , HepG2 cells, and p oten tia lly  
other tissu es . (Endocrinology 148: 2984-2993, 2007)
Activation of gene expression by steroid hormone receptors 
generally involves binding of receptor homodimers to spe­
cific, ds-acting DNA sequences. The DBD of the AR, MR, PR, 
and GR is highly conserved and contains two zinc-binding 
modules. The first has the primary role in DNA binding, 
whereas the second has been suggested to have dual func­
tions in DNA binding and in stabilization of receptor ho­
modimers (1 1 ).
Steroid hormone receptors bind a consensus steroid hor­
mone response element (SRE) (GG A ACA nnn TGTTCT) con­
sisting of two receptor-binding half-sites organized as in­
verted 6 -bp repeats separated by three nucleotides (1 2 ). 
Although AR, GR, PR, and MR all bind such consensus 
sequences, naturally occurring binding sites for these recep­
tors often diverge from the consensus sequence, providing 
one mechanism for specificity of receptor action at target 
genes (13-15). Androgen response elements (AREs) may con­
sist of classical inverted repeats, but specificity for androgens 
has been associated with AREs that include direct repeats
(16) or several contiguous AR-binding sites, each composed 
of sequences based on the consensus SRE (17). Similarly, 
features of glucocorticoid response elements that minimize 
activation by androgens include binding sites with overlap­
ping sequences for GR half-sites (15). Specificity of binding 
of SREs to specific steroid hormone receptors may be further 
enhanced by interactions of sequences flanking the SRE with 
the second zinc finger of the DBD or the hinge region sep­
arating the DBD and ligand-binding domain (11, 18).
Mechanisms by which testosterone or its analogs increase 
FGF-F expression have not been examined. The FGF-F gene is 
under a complex system of transcriptional control in which 
two alternative promoters exist, one in exon 1 with the other
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being in exon 2. These promoters are used in a tissue-specific 
manner (19). Both promoters seem to be used in liver and 
kidney, whereas only that in the first exon is employed in 
most other tissues. The exon 1 promoter has four transcrip­
tional start sites, with the third being predominately used
(19). Here, we tested the hypothesis that the androgen re­
sponsiveness of the 1GF-1 gene is attributable to AREs in the 
proximal promoter of this gene.
Materials and Methods
Plasm ids
pRHP4.hAR, expressing full-length hum an AR, and pCMV.Sport.|3- 
Gal, expressing |3-galactosidase under a CMV prom oter, w ere as de­
scribed (20). pcDNA5.rGR, expressing rat GR, and pSP72hAR-1, con­
taining an insert of the  full-length cDNA clone of the hum an AR, were 
gifts from Dr. Diane Robins (University of M ichigan). A vector express­
ing rat AR with a C562G m utation in the DBD (rARC562G) leading to 
loss of DNA binding (21, 22) was provided by Dr. Jorma Palvimo 
(University of Helsinki). The IGF-I reporter genes pOT.uc.163Q, 
pOT.uc13QQ, and pOT.uc926 (23) w ere generously provided by Dr. Peter 
Rotwein (Oregon Health and Science University). These reporters ex­
pressed firefly luciferase under the control of 926-1630 bases upstream  
of the  transcriptional start site of the hum an IGF-I prom oter. pGKX 4T-1 
hAR2, expressing glutathione-S-transferase (GST) fused to the N  ter­
m inus of AR-DBD (24), was a generous gift from Dr. Robert J. M atusik 
(Vanderbilt University). The pBabe.puro retroviral backbone (25) with 
a Notl site introduced into the polylinker was a generous gift of Dr. 
Robert Kraus (M ount Sinai School of M edicine). pRI.-CMV expressing 
Renilla luciferase was from Prom ega (M adison, WI).
Cell culture
Cell lines were from the American Tissue Type Collection (Bethesda, 
MD). I.NCaP cells were m aintained a t 37 C in hum idified air supple­
m ented with 5% carbon dioxide using RPMI 1640, 10% fetal bovine 
serum  (FBS), and antibiotics (100 U /m l penicillin, 100 /xg/m l strepto­
mycin). HepG2 cells w ere m aintained in hum idified air containing 10% 
carbon dioxide using DMKM supplem ented with 10% FBS and 
antibiotics.
Effect o f  testosterone on IGF-I  m R N A  levels
Incubations o f cells and extraction o f RNA.  Cells were seeded into wells of 
six-well plates at 3 X 10h cells per well in m edium  supplem ented with 
10% charcoal-dextran-stripped FBS (CDS-FBS) and incubated overnight. 
Steroid horm ones or ethanol were added , and cells were incubated 
overnight. For these experim ents, and all others described below, so­
lutions of testosterone were prepared freshly on the  day of the exper­
im ent because prelim inary studies indicated th a t this horm one began to 
lose activity in ethanol within 24 -4 8  h. Total RNA was extracted from 
cultured cells using RNeasy colum ns (QIAGHN, Valencia, CA) after 
d isruption  of cells with Q IA shredder colum ns (QIAGHN), freed of re­
sidual DNA by digestion on the colum n with RNase-free DN ase (QIA­
GHN), and eluted with water.
Real-time PCR. RNA was quantified by absorbance at 260 nm. One 
microgram  of total RNA was used to  p repare cDNA libraries using the 
High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, C A)
in a total volum e of 20 pd. Libraries w ere diluted 25-fold with water. 
Real-time PCR w as perform ed with 12.5-/xl reactions using TaqM an 2X 
PCR buffer (Applied Biosystems) and an Applied Biosystems 7500 ther­
mocycler following the  m anufacturer's recom m ended procedures. Data 
were norm alized relative to  that for 18S RNA. TaqM an Assay on De­
m and probes (Applied Biosystems) w ere used for all assays. All deter­
m inations were perform ed in triplicate. M ean values for crossing points 
for the  replicates were used in subsequent calculations. Levels of IGF-I 
mRNA w ere expressed relative to those in vehicle-treated cells using the 
2 -AAct nle(-|10C] 2^6).
HepG2 cells stably expressing A R
The retroviral backbone expressing hum an AR (pBabe hAR) was 
constructed by ligating the B^/II-X'tol fragm ent of pSP72hAR-1, includ­
ing the com plete coding region for the hum an AR, into the Bam'HI and 
HmdTIT sites of the pBabe puro  vector (pBabe.puro.h AR). This construct 
was cotransfected together with vectors expressing gag-pol and VSV-G 
into 293T cells. The supernatants w ere harvested, and the cell debris was 
removed by centrifugation at 500 X g. The supernatan t was used to  infect 
HepG2 cells after addition of polybrene (4 /xg/m l final concentration). 
After 24 h, purom ycin (1000 n g /m l) was added to the culture m edium  
and was present thereafter during  culture and propagation of these cells. 
Pooled HepG2.AR cells w ere used for experim ents after 1 wk of d rug  
selection.
Luciferase assays
Cells w ere seeded at 5 X 104 cells per well into wells of 24-well plates 
containing m edia supplem ented with 10% CDS-FBS. The next day, cells 
were transfected with a total of 300 ng DNA per well using Lipo- 
fectam ine Plus (Invitrogen, C arlsbad, CA) with plasm ids as indicated in 
the figure legends. Three hours after transfection, cells w ere covered 
with m edia supplem ented with 10% CDS-FBS and either horm one dis­
solved in ethanol, or ethanol, as indicated in the figures. After overnight 
incubation, activities of firefly and Renilla luciferase were determ ined 
using the Dual Luciferase Assay system (Promega).
Construction o f  reporter genes
R eporter genes expressing firefly luciferase under the control of up ­
stream  regions of the  IGF-I prom oter were constructed by PCR am pli­
fication of segm ents of interest using prim ers show n in Table 1, using 
pOLuc-1630 as a tem plate. PCR amplification was conducted using a 
high-fidelity Taq polym erase (Pfx; Invitrogen). PCR products were 
cloned into pCR2.1-TOPO TA (Invitrogen), and the  sequences of the 
inserts were verified. Inserts w ere excised with Kpn\ and X7wl and were 
subcloned into pGL3-Promoter (Promega) at these sam e sites. pGL3- 
Prom oter expresses firefly luciferase under the control of a m inimal 
prom oter.
G ST-hAR-D BD  expression a n d  purification
BL21:Des were transform ed with pGHX 4T-1 hAR2, which encodes a 
GST-AR-DBD fusion protein under control of a Lac operon. A single 
colony was picked and grow n at 37 C overnight in LB broth (5 ml) and 
then diluted 1:10 into 50 ml of this broth and grow n 1 h at 37 C. 
Isopropyl-|3-D-thiogalactopyranoside w as added at a final concentration 
of 1 m M . Cells were incubated for 2 h at 20 C, collected by centrifugation 
(5000 X g forlO min at 4 C), and frozen. Recom binant GST-AR-DBD w as 
liberated using B-PHR Bacterial Protein Extraction Reagent (Pierce,
TABLE 1. Primers used for amplification of regions of the human IGF-1 upstream promoter
Amplieon Construct Forward primer (S'—3') Reverse primer (5'—«3')
1 pGL3-13a catagtgcaccattgacacaacat tg a g tc t tc tg tg tg g t ta a ta c a t tg
2 pGL3-210 ggtaccccaaagcctctcatgaca gg tcaag tccc ttca ggggc tttca gc
3 pGL3-22 caca tgccca tca ta tgactg tgaag gaaagaggaataagatatggtcaagtc
4 pGL3—2 3 0 ggtaccccaaagcctctcatgacac gaaagaggaataagatatggtcaagtc
5 pGL3-25a catagtgcaccattgacacaacat tg a g tc t tc tg tg tg g t ta a ta c a t tg
6 pGL3—32 gggcacatagtagagctcacaaaatg tg a g tc t tc tg tg tg g t ta a ta c a t tg
The location of each amplified fragment is relative to the transcriptional start site.
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Rockford, IT.) following procedures recom m ended by the m anufacturer. 
The supernatan t obtained after centrifugation (15,000 X g for 10 min) 
was incubated (20 C for 30 min) with 1 ml 50% (w t/vo l) glutathione- 
agarose beads with gentle mixing. The beads were washed three tim es 
with 10 ml ice-cold PBS. The fusion proteins were eluted by suspending 
the beads in 0.5 ml 50 m M  Tris-HCI (pH  8.0) containing 15 mM  reduced 
glutathione followed by incubation a t 20 C for 4 min followed by cen­
trifugation. Protein was stored at 4 C until use.
E M S A s
Oligonucleotides were NF-kB, 5'-AGTTGAGGGGACTTTC-3' and 
5'-GCCTGGGAAAGTCCCC-3' (27); Oct-1, 5'-TGTCGAATGCAAAT- 
CACT-3' and 5'-TTCTAGTGATTTGCATTC-3' (28, 29); and SRK, 5'- 
ATGCATTGGGTACATCTTGTTCACATAGACA-3' and 5'-TGTCAA- 
CAAGATGTACCCA-3' (30). Sequences of all o ther probes used are 
show n in Fig. 7. Synthetic sense and antisense strands were annealed 
and then labeled with [y,2P]dC TPby filling in the ends using the Klenow 
fragm ent of Escherichia colt DNA polym erase (New England Biolabs, 
Ipswich, MA) in the presence of dN TPs at 37 C for 30 min. Probes were 
purified using ProbeQ uant G-50 Micro C olum ns (Am ersham  Bio­
sciences, Piscataway, NJ) and eluted from the colum ns with water. 
Protein-DNA com plexes were form ed by incubation a t 4 C for 30 min 
of recom binant GST-AR-DBD (16 jug) with 1 pmol 32P-!abe!ed probe and
2 jug poIy-dl-dC in b inding buffer (5% glycerol, 1 m M  MgCU, 0.5 mM  
KDTA, 0.5 mM  dithiothreitol, 50 m M  NaCI, 10 mM  Tris-HCI, pH  7.5). 
Some reactions were supplem ented with unlabeled SRK (1, 2, 4, or 6 
pmol). Com plexes were resolved by nondenaturing electrophoresis for
10 min a t 350 V with cooling on 5% polyacrylam ide m inigels containing 
0.25X Tris-borate KDTA and visualized by phosphorim aging. Densi­
tom etry scanning was perform ed using Im agequantT I, (GK Healthcare, 
Fairfield, CT). For each labeled probe, densities of bands in the presence 
of a com peting SRK probe were norm alized relative to densities for 
bands in the absence of com petitor. The concentration of SRK causing a 
50% reduction in binding of ARK1 or A R E  w as calculated by fitting the 
data to the curve for a one-site com petition m odel using Prism 4.0b 
(GraphPad Software, San Diego, CA).
Chromatin immunoprecipitation
H epG 2orI,N C aP ceIIs(2  X 10" ) w ere seeded into 150-mm dishes and 
incubated until confluent. M edium  w as replaced with fresh m edium  
(RPMI or DMKM for LNCaP and HepG2, respectively) supplem ented 
with 10% CDS-FBS and either 50 iim  testosterone or ethanol. Cells were 
incubated overnight followed by chrom atin im m unoprecipitation using 
a commercially available kit (Upstate, Charlottesville, VA) according to 
the m anufacturer's instructions. Im m unoprecipitation w as conducted 
with rabbit polyclonal anti-AR antiserum  (Santa C ruz Biotechnology, 
Santa Cruz, CA) or with norm al rabbit serum . Im m unoprecipitated 
DNA was eluted with high salt followed by detection of sequences 
containing ARK1 and ARK2 using prim ers em ployed to am plify se­
quences in pGI,3-32 (Table 1).
Statistics
Data are expressed as m ean values ±  sem . C om parisons betw een two 
m eans w ere perform ed using a S tudent's t test. C om parisons am ong 
m ultiple m eans were perform ed using one-way ANOVA with post hoc 
testing by the New m an-K euls test. The significance of differences be­
tween values obtained for tw o fitted curves w as determ ined using an F 
test. W here data w ere fitted to more than  tw o curves, the significance 
of differences betw een pairs of mean values w as determ ined by one-way 
ANOVA followed by the New m an-K euls test. Statistical calculations 
were perform ed using Prism 4.0b.
Results
To confirm that testosterone increased IGF-I mRNA levels, 
effects of overnight incubation with testosterone on mRNA 
levels were determined for LNCaP and HepG2 cells. LNCaP 
cells constitutively express AR at levels sufficient to modu­
late gene expression. Although HepG2 cells are reported to
express AR (31), in preliminary experiments, the level of 
expression was found to be below that needed to achieve 
testosterone-induced induction of reporters with known 
AREs such as MMTV-Luc. To permit us to assess the effects 
of testosterone on IGF-I mRNA levels in HepG2 cells, a 
retrovirally transduced version of these cells that stably ex­
press human AR was used (HepG2. AR cells). Levels of IGF-I 
mRNA were increased significantly by testosterone in both 
LNCaP (Fig. 1A) and HepG2.AR (Fig. IB) cells. The possi­
bility that testosterone increased transcription of the IGF-I 
gene was tested by determining whether testosterone altered 
the expression of a reporter gene expressing firefly luciferase 
under the control of 1 . 6  kb of the proximal promoter of the 
human IGF-I gene (pOLuc.1630). Testosterone significantly 
increased reporter gene activity in both cell types (Fig. 1, C 
and D). To establish whether the AR was necessary for 
testosterone-induced increases in reporter gene activity, 
HepG2 cells were cotransfected with pOLuc.1630 and either 
a vector expressing the human AR or one expressing j3-ga- 
lactosidase and then incubated overnight with testosterone 
or vehicle and assayed for luciferase expression. Testoster­
one had no effect on luciferase expression in cells cotrans­
fected with j3-galactosidase but caused a significant increase 
in expression in cells expressing AR (Fig. IE).
These data indicate the presence of AR-dependent andro­
gen-responsive sequences within the first 1.6 kb of the IGF-I 
upstream promoter. To localize the androgen-responsive se­
quences, this analysis was repeated using HepG2 cells and 
a series of reporter genes with 5' truncations that removed 
between 300 and 900 bases from the 5' end of the original 
1.6-kb insert (Fig. 2). Androgen responsiveness was lost com­
pletely with removal of 300 bases from the 5' terminus of the 
insert, indicating that the AREs are localized to between
— 1300 and —1600 bases upstream of the first codon of the 
IGF-I gene.
Inspection of the sequence of the androgen-responsive 
region of the IGF-I gene revealed two regions (ARE1 and 
ARE2, bold in Fig. 3) with similarities to the AREs of the Pem 
homeobox gene (30). To explore the possibility that these 
sequences represent authentic AREs, additional reporter 
genes were constructed by ligating sequences containing 
ARE1, ARE2, or both into pGL3-promoter, a reporter con­
struct expressing firefly luciferase under the control of a 
minimal promoter (Fig. 4). HepG2 cells were then transfected 
with these reporter genes together with AR, and effects of 
incubation with testosterone on reporter gene activity were 
determined. Testosterone led to a more than 5-fold increase 
in expression of luciferase by reporter genes with inserts that 
included upstream sequences and ARE1 (pGL3-230 and 
pGL3-22 in Fig. 4). Testosterone responsiveness of a reporter 
gene with an insert containing only sequences upstream of 
ARE1 (pGL3-210) was reduced compared with that for 
pGL3-22 or pGL-230 (Fig. 4). Testosterone increased lucif­
erase expression by more than 2 0 -fold for the construct con­
taining ARE2and downstream sequences (pGL3-13A in Fig. 
4), whereas little androgen responsiveness was observed 
with a reporter under control of sequences beginning just 
downstream of ARE2 (pGL3-25a in Fig. 4). The greatest 
induction was observed when cells were transfected with a 
reporter containing both ARE1 and ARE2 (pGL3-32 in Fig.
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F ig .  1. The hum an IGF-I gene is an­
drogen responsive. A, LNCaP cells were 
incubated overnight with testosterone 
a t the concentrations indicated, or with 
vehicle, followed by quantitation of 
IGF-I mRNA. D ata are from two exper­
im ents performed in duplicate. *, P  < 
0.05 vs. vehicle. B, HepG2.AR cells 
were incubated overnight with testos­
terone or vehicle. Levels of IGF-I 
mRNA were then quantified. D ata are 
from two experiments, each performed 
in duplicate. C, LNCaP cells were co­
transfected with pOLuc.1630 and 
pCMV-Renilla and then incubated 
overnight with testosterone or vehicle. 
D ata are from three experiments with 
six replicates each. *, P  < 0.05 vs. ve­
hicle. D, HepG2 cells were cotrans­
fected with pOLuc.1630, pCMV.Re- 
nilla, and pREP4.AR and then 
incubated overnight with testosterone 
or vehicle. D ata are from four experi­
m ents, each with six replicates. E, 
HepG2 cells were cotransfected with 
pOLuc-1630, pCMV-Renilla, and vec­
tors expressing either 0-galactosidase 
or AR. Cells were incubated overnight 
with testosterone (50 nM ) or vehicle. 
D ata are from a t least three experi­
m ents, each performed in triplicate. *, 
P  < 0.05 vs. vehicle. EtOH, Ethanol.
4). These data are consistent with the presence of two 
androgen-responsive sequences located between —1420 and
— 1320 upstream of the first codon of the IGF-I gene.
The greater testosterone responsiveness of constructs con­
taining both AREs, as opposed to either one alone, suggested 
the possibility of interactions between the two elements. To
F ig .  2. Androgen responsiveness is ablated by 5' truncation. Left, Map of the IGF-I gene and constructs used. Arrow s  indicate the approximate 
location of the four transcriptional s ta rt sites w ithin exon 1, w hereas the black box indicates the s ta rt of the coding sequence (19). R ig h t, HepG2 
cells were cotransfected with pOLuc-1630, or derivatives having 5 ' truncations of the 1630 bp IGF-I prom oter insert, together with pCMV-Renilla 
and a vector expressing AR. After incubation overnight w ith testosterone (Ts) or vehicle, luciferase activities were determined. D ata are from 
at least th ree experiments, each having three replicates. *, P  < 0.05 vs. ethanol (EtOH) (f test).
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Fig. 3. Map of the androgen-responsive region of the hum an IGF-I 
upstream  promoter. Sequences of the two proposed AREs are shown 
in bold. A rrow s  indicate regions of the IGF-I promoter included in  the 
various reporter genes.
test for interactions more explicitly, cells were transfected 
with reporter genes under the control of ARE1, ARE2, or both 
and then incubated with increasing concentrations of testos­
terone (Fig. 5). Data were fitted to a curve assuming a one-site 
binding model. Values for EC50 were similar for constructs 
containing ARE2 compared with the construct containing 
both ARE1 and ARE2 (0.098 and 0.09 n M , respectively) and 
were significantly less than the EC50 for the construct con­
taining ARE1 (0.68 n M , P <  0.001). Values for maximal re­
porter activity are each significantly different from values for 
the other two reporters and were greatest for the reporter 
containing both AREs (23.9) followed by a reporter contain­
ing ARE2 (15.0) and one containing ARE1 (10.0). The findings 
argue against synergist interactions on AR binding but are 
consistent with additive effects of the two AREs on tran­
scriptional activation.
To determine whether these effects of androgens de­
pended upon binding of the AR to specific DNA sequences 
within these two elements, the ability of testosterone to in­
duce expression of reporter genes containing them was 
tested in cells transfected with a mutant AR with impaired 
DNA binding due to a C ^ G  mutation in the fourth cysteine
Fig. 5. Interactions between IGF-I AREs. HepG2 cells were cotrans­
fected w ith the indicated reporter genes, pRL-CMV, and a vector 
expressing AR and then  incubated with testosterone a t the indicated 
concentrations or w ith ethanol (EtOH). The curves shown were fitted 
assum ing a one-site binding model; values for R2 were as follows: 
pGL3-13A, 0.93; pG L3-32,0.98; pG L3-230,0.95. Data are from three 
different experiments each w ith a t least two replicates.
of the first zinc finger within the DBD (22) (AR-C562G). 
HepG2 cells were cotransfected with a vector expressing the 
mutant AR, and reporter genes containing ARE1 (pGL3-22), 
ARE2 (pGL3-13A), or both (pGL3-32). As a control, addi­
tional experiments were conducted in which cells were co­
transfected with these reporters and a vector expressing 
wild-type AR. For each of the three reporter genes tested, 
induction of luciferase expression was virtually abolished 
when wild-type AR was replaced with the DBD mutant (Fig. 
6 A), consistent with a requirement for binding of AR to DNA 
sequences within ARE1 and ARE2 for transactivating 
activity.
To more directly test whether the AR bound to sequences 
with ARE1 and ARE2, binding of a GST-tagged version of 
recombinant AR-DBD to radiolabeled probes was examined 
using EMSAs. As expected, incubation of the AR-DBD with 
probes having the SRE consensus sequence yielded a com­
plex that was diminished in amounts by the addition of 
excess unlabeled probe (Fig. 6 B). Incubation with a probe 
including the sequence of either ARE1 or ARE2 yielded a 
band with a similar mobility to that observed for SRE (Fig. 
6 B). Intensity of the bands for ARE1 and ARE2 was dimin­
ished by unlabeled DNA having the sequence of the con­
sensus SRE. No complex was apparent after incubation of the 
AR-DBD with probes containing irrelevant sequences con­
sisting of the consensus binding site for either NF-kB or Oct-1 
(Fig. 6 C). These findings indicate specific binding of the IGF-I
Fig. 4. Androgen responsiveness of 
the putative IGF-I AREs. L e ft , Map of 
reporter constructs tested. R ectangles 
indicate the approximate position of 
putative AREs in the hum an IGF-I pro­
moter. R ig h t , HepG2 cells were co­
transfected w ith the indicated reporter 
constructs together w ith pCMV-Renilla 
and a vector expressing AR and then 
incubated overnight w ith testosterone 
(50 nM) or vehicle. D ata are from at 
least three different experiments each 
performed in a t least triplicate. *, P  < 
0.05 vs. ethanol (EtOH) (t test).
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F ig .  6 . The AR binds to ARE1 and ARE2 
in vitro. A, HepG2 cells were cotrans­
fected with a vector expressing m utan t 
AR th a t is unable to bind DNA (pC562G) 
or wild-type AR together with the indi­
cated reporter gene and pRL-CMV and 
then incubated overnight with testoster­
one (50 nM) or ethanol (EtOH). D ata are 
from three separate experiments each 
performed a t least two times. B, GST-AR- 
DBD was incubated with radiolabeled oli­
gonucleotides as indicated in the absence 
or presence of excess unlabeled oligonu­
cleotide with the SRE consensus sequence 
and then subjected to EMSA. The arrow  
indicates th e  band representing AR-oligo- 
nucleotide complexes. Probes 2 and 8 in 
Fig. 7B were used for ARE1 and ARE2, 
respectively. The gel shown is represen­
tative of two separate experiments. C, 
GST-AR-DBD was incubated with the in­
dicated radiolabeled oligonucleotides and 
then subjected to EMSA. The arrow  indi­
cates th e  position of the AR-DBD-SRE 
complex. The gel shown is representative 
of findings in two separate experiments.
D, GST-AR-DBD was incubated with ra ­
diolabeled oligonucleotides with or w ith­
out unlabeled SRE as indicated and then 
resolved by nondenaturing electrophore­
sis. E, Intensities of bands in D were as­
sessed by densitom etry scanning. Binding 
in th e  presence of each am ount of SRE was 
expressed as a fraction of binding without 
SRE. The curves shown were fitted using 
a one-site competition model. Values for 
R2 were as follows: ARE1, 0.94; ARE2, 
0.96. D ata are from th ree separate exper­
iments.
ARE1 and ARE2 to the AR-DBD, consistent with the inter­
pretation that these DNA sequences represent rfs-acting el­
ements bound by the AR.
The relative binding affinities of ARE1, ARE2, and SRE 
were assessed by comparing the reduction in binding ob­
served upon the addition of increasing amounts of excess, 
unlabeled SRE probe (Fig. 6 , D and E). The concentration of 
SRE reducing binding by 50% was significantly greater for 
ARE1 than for ARE2 (8.2 n M  for ARE1 vs. 2.1 n M  for ARE2, 
P <  0.016), indicating that affinity of the AR was significantly 
greater for ARE1 than for ARE2.
Fn an effort to further localize sequences within each ARE 
that bound to AR, binding of to GST-AR-DBD of truncated 
probes based on sequences within ARE1 or ARE2 was ex­
amined (Fig. 7, A and B). A 5' truncation of the original 36-bp 
ARE1 probe that removed the sequence GACTT (lanes 3 and
5, Fig. 7A)  prevented binding. Addition of eight bases to the 
3' end of the probe did not appreciably increase binding (lane
6 , Fig. 7A). Fn the case of the 37-bp ARE2 probe, a 3' trun­
cation removing nine bases greatly diminished binding, 
whereas a 5' deletion removing this number of bases blocked 
binding completely (lanes 8  and 9, Fig. 7A).
These findings suggest that binding involves extended
interactions between the AR and ARE1 /ARE2. These find­
ings could be explained by interactions of sequences flanking 
the DBD-binding motif with other domains of the AR (11) 
an d /o r by the presence of multiple half-sites within each 
ARE (15,17). Accordingly, sequences within each ARE were 
inspected more closely for potential steroid hormone recep­
tor-binding motifs (Fig. 8 ) similar to known AREs. Each ARE 
contained several half-sites (Fig. 7, A and B) similar to either 
a consensus SRE or to half-sites within other known AR- 
binding sites. Three such motifs were found in ARE1 (num­
bered 1-3 in Fig. 8 ), and an additional four motifs were 
identified within ARE2 (numbered 4 -7  in Fig. 8 ). Assuming 
a usual spacer of 3 bp, each half-site appeared to be associ­
ated with a second half-site with a degenerate sequence 
lacking C /G  in either position 3 or 5. Fntriguingly, the po­
tential binding sites were overlapped in both ARE1 and 
ARE2.
Within ARE1, the left half-site of the first binding site 
(labeled 1 in Fig. 8 ) closely resembled the consensus TGTTCT 
motif of the consensus SRE (Fig. 8 ), whereas the left half-site 
of the second site (labeled 2 ) was similar to the right half-site 
of theh AR ARE1. The third potential site (labeled 3) included 
a degenerate left half-site, with a right half-site similar to the
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Fig. 7. Evidence that binding interactions are extended beyond the 
DBD. A, GST-AR-DBD was incubated with radiolabeled probes in­
corporating ARE1 (probes 1-6) or AEE2 (probes 7-9) and then sub­
jected to EMSA. Arrow  indicates the position of the AR-oligonucle- 
otide complex. Gels are representative of results from two separate 
experiments. B, Sequences of the oligonucleotides used in studies in 
A; bold sequences are those similar to the AREs of the Pem gene (see 
Fig. 3).
left half-site of the ARE in the Cl gene. The organization of 
this site as one half-site downstream of an incomplete half­
site has also been observed in the first ARE from the Sip gene
(32) and the JRE element (33) (Fig. 8 B). Consideration of 
spacers shorter than three, or up to six, did not reveal com­
binations of half-sites more closely resembling classical 
AREs.
The first site in ARE2 (labeled 4) resembled an inversion 
of the consensus SRE but was degenerate in having a G in 
position 1 of the second half-site. A second motif (labeled 5) 
had a left half-site similar to the probasin ARE2 right-hand 
half-site. A third motif (labeled 6 ) had a degenerate left 
half-site with a right half-site similar to the hAR ARE1 right­
handed half-site. The final motif (labeled 7) also contained a 
degenerate left half-site, with a right half-site similar to the 
Cl ARE, and the Pem ARE2 left-handed half-site. Of interest, 
if one assumed a spacer of six bases, the right half-site of this 
motif can be paired with the left half-site of the previous 
motif, yielding a sequence in which both half-sites contain 
G /C  in positions 2 and 5 and in which the half-sites are 
arranged as a direct repeat (GGCACA tagtag AGCTCA).
Ff ARE1 and ARE2 contribute to testosterone-induced in­
creases in FGF-F in intact cells, it would be predicted that 
testosterone would cause recruitment of the AR to the region 
of genomic DNA containing these AREs in intact cells. This
A
ARE 1 TGAAGGGACTTGACCATATCTTATTCCTCTTTGAAAAGGATC
^ ___  ___ ►  (1) ACTTGA CCA TATCTT
(2) TGACCA TAT CTTATT 
-----  ----- ►  (3) ATATCT TAT TCCTCT
TTGTAGTTGGGCACATAGTAGAGCTCAGTTTTACAA
m  ---- ►  (4) TGTAGT TTG GGCACA
----- to- (5) AGTTGG CAC CATAGT
-----  ------ to- (6) GCACAT AGT AGAGCT
-----  ----- to- (7) ACATAG TAG AGCTCA
ARE2
B
SRE Consensus GGAACA nnn TGTTCT
IGF--1 AREs
(1) ARE1-1 ACTTGA CCA TATCTT
(2) ARE1-2 TGACCA TAT CTTATT
(3) ARE1-3 ATATCT TAT TCCTCT
(4) ARE2-1 TGTAGT TTG GGCACA
(5) ARE2-2 AGTTGG CAC CATAGT
(6) ARE2-3 GCACAT AGT AGAGCT
(7) ARE2-4 ACATAG TAG AGCTCA
Pem ARE-1 AGATCT CATTC TGTTCC [34]
Pem ARE-2 AGCACA TCG TGCTCA [34]
Cl AGGACA CAA AAATCC [43]
hAR ARE-1 CTTTCT GAA TGTCCT [44]
hAR ARE-2 AGTACT CCT GGATGG [44]
Sip ARE-1 GTAATT ATC TGTTCT [36]
JRE ARE ATTACA CCA AGTACC [37]
PB ARE1 ATAGCA TCT TGTTCT [41]
PB ARE2 AGTACT CCA AGAACC [41]
Fig. 8. A, Analysis of sequences within ARE1 and AEE2. Thick ar­
rows indicate the location of half-sites resembling either a consensus 
SRE or half-sites in known AREs (B). Thin arrows indicate the lo­
cation of degenerate half-sites. Bold characters indicate the location 
of sequences similar to AREs of the Pem gene. B, Sequences of IGF-I 
ARE1/2 binding sites and selected known AREs taken from the cited 
literature.
prediction was tested in LNCaP and HepG2.AR cells using 
chromatin immunoprecipitation. This analysis revealed that 
a PCR product containing ARE1 and ARE2 was obtained 
when chromatin immunoprecipitation was performed with 
antibodies against AR (Fig. 9, A and B) but not when chro­
matin immunoprecipitation was done using normal rabbit 
serum. Moreover, amounts of the PCR product were in­
creased by addition of testosterone, indicating that testos-
Fig. 9. The AR is recruited to IGF-I AREs in intact cells. Represen­
tative gels are shown. Each gel is representative of at least two 
experiments. Cells were incubated overnight with testosterone (50 
nM) or vehicle followed by chromatin immunoprecipitation using ei­
ther normal rabbit serum or anti-AR and PCR primers flanking the 
sequence containing ARE1/2.
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terone induced the recruitment of the AR to chromatin con­
taining ARE1 and ARE2.
AREs are also typically bound by GR resulting in tran­
scriptional activation. Conversely, the sequence of AREs pro­
vides one means of discriminating AR from other steroid 
hormone receptors, such that transactivation of GR bound to 
AREs is often lower than that for AR. The ability of GR to 
cause transcriptional activation of reporter genes incorpo­
rating ARE1, ARE2, or both was therefore tested. Dexameth- 
asone induced only weak induction of luciferase expression 
(less than 2 -fold) in cells transfected with reporter genes 
incorporating ARE1 (p3-230 and p3-22 in Fig. 10B) com­
pared with more than 5-fold increases observed in cells 
treated with testosterone (Fig. 10A). Stronger activation by 
glucocorticoids (5-fold) was observed for the reporters in­
corporating ARE2 or both AREs (p3-13a and p3-32, respec­
tively), although activation remained more than 5-fold less 
than that observed for cells transfected with the same re­
porter genes and treated with testosterone (approximately 
20- and 30-fold, respectively).
Discussion
The above findings provide evidence that, in hepatocytes 
and prostate epithelium, IGF-I is up-regulated by testoster­
one as a consequence of recruitment of the AR to two ris- 
acting DNA elements within the IGF-I promoter upon bind­
ing of testosterone to the AR. These elements are localized 
between —1320 and —1420 bases upstream of the first codon 
of the human IGF-I gene. Evidence supporting this conclu­
sion includes findings that sequences from within the an­
drogen-responsive region that contained one or both ele­
ments conferred strong activation by testosterone of reporter 
genes. Additionally, transcriptional activation via each of 
these androgen-responsive regions required a functional AR- 
DBD, and the AR was found to bind to DNA sequences 
within each of the elements. Moreover, in intact cells, tes­
tosterone caused recruitment of the AR to the DNA se­
quences containing them.
Our findings that testosterone up-regulates IGF-I expres­
sion in LNCaP and HepG2 cells are consistent with results 
from other studies that have examined the effects of andro­
gens on expression of this gene. Up-regulation of IGF-I ex­
pression has been observed after exposure of prostate stro­
mal cells or LNCaP cells to physiological concentrations 
(10-35 nM) (34) of testosterone (7, 8 ). Muscle satellite cells 
were also found to express higher levels of IGF-I mRNA after 
exposure to testosterone or to trenbolone, an anabolic steroid
(5). These findings in cultured cells appear to have relevance 
for tissues. Testosterone administration led to more than 
30-fold increases in uterine IGF-I mRNA levels (6 ). In elderly 
men with lower than normal concentrations of testosterone 
in blood, testosterone replacement therapy increased skeletal 
muscle expression of IGF-I mRNA and protein (2,3), whereas 
in young men, ablation of testosterone production signifi­
cantly reduced levels of IGF-I mRNA in skeletal muscle (4).
Although we observed increased IGF-I mRNA levels in 
HepG2 cells exposed to testosterone, and the liver is the 
primary source of IGF-I in blood, reports regarding the ef­
fects of testosterone on liver expression and secretion of IGF-I 
have reached conflicting conclusions. Studies of the effects of 
testosterone on hepatic IGF-I expression have been con­
ducted in male peripubertal rats. When begun 1 wk after 
hypophysectomy, testosterone did not alter liver IGF-I 
mRNA levels or blood IGF-I levels (35). Similarly, no change 
in hepatic IGF-I expression was observed when testosterone 
was administered after castration with or without hypoph­
ysectomy (35). Testosterone did not alter blood IGF-I levels 
after castration and hypophysectomy and caused a small 
decline (14%) after castration only. Conversely, testosterone 
administration was found to increase IGF-I protein levels in 
blood in healthy young men (1 ).
The presence in the IGF-I gene of multiple AREs is similar 
to other genes where ris-acting DNA sequences are known 
to be involved in transcriptional activation by the AR (30, 
36-38). These multiple AREs act together to control tran­
scription in several different ways. In the probasin gene, 
cooperative interactions between AR bound to these differ­
ent sites increases receptor-binding affinity for DNA at the 
two sites (24,39). By contrast, in the Sip gene, only one of the 
three AREs is able to mediate transcriptional activation in 
isolation from the others, with activity of that consensus ARE 
being somewhat enhanced by one of the flanking, degenerate 
AREs while being repressed by the other (32). In the case of 
the AREs of the IGF-I gene, each ARE conferred testosterone- 
induced activation. The presence of both AREs did not seem 
to alter EC50 for activation by testosterone but did increase 
maximal activation achieved by testosterone. Transcriptional 
activation has been suggested to depend on multiple binding 
affinities that include those between the AR and DNA as well 
as between AR and other transcription factors (37) or be­
tween AR and coregulators. The EC50 would be expected to 
result in the sum effect of receptor affinity for DNA and 
receptor interactions with other transcription factors, coac­
tivators, and corepressors; it would be predicted that coop­
Fig. 10. Comparison of transactiva­
tion at ARE1 and ARE2 by AR and GR. 
HepG2 cells were cotransfected with 
the indicated reporter genes, pCMV- 
Renilla, and a vector expressing either 
AR or GR and then incubated overnight 
with hormone as indicated. Dex, Dexa- 
methasone; EtOH, ethanol; Ts, testos­
terone. Data are from three separate 
experiments, each performed at least 
two times.
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erative interactions between receptors would therefore re­
duce EC50. Therefore, our findings argue against cooperative 
binding interactions between receptor and the two AREs and 
indicate instead additive effects of the two AREs on tran­
scriptional activation.
Although a general relationship between AR binding af­
finities for DNA and transcriptional activation might be pre­
dicted, divergence from such a relationship could reasonably 
be expected to occur, and many disparities between these 
measures have been observed. For example, the binding 
affinities of the steroid hormone receptor DBDs to oligonu­
cleotides based on the probasin ARE2 or C3(l) ARE were 
poor predictors of transcription activation of reporter genes 
based on these AREs in cultured cells. Similarly, ARE2 of the 
IGF-I bound AR with lower affinity but achieved greater 
transcriptional activation upon binding of AR.
The structure of the two AREs was complex and diverged 
from that of consensus SREs and most known AR-binding 
sites. Sequences within each ARE included what appeared to 
be overlapping half-sites resembling those in the consensus 
SRE, or in other known AREs, each linked to a second half­
site markedly diverging from the consensus SRE sequence 
and unlike other known AREs described in the literature (24, 
30, 40, 41). These overlapping motifs were compressed into 
approximately 18 bp of sequence, suggesting that only one 
AR dimer binds within each ARE at any one time. Our 
analysis does not exclude the possibility that a longer spacer 
is present between the two half-sites, and one motif consist­
ing of a direct repeat with a spacer of six bases was observed 
in ARE2. Of note, ARE1 from the Pern gene includes a spacer 
of five bases, and the GR has been observed to bind motifs 
with up to nine base spacers (16), suggesting that the motif 
in ARE2 with an extended spacer may function in AR bind­
ing. It is both intriguing and unusual that binding of ARE1 /  
ARE2 to the AR required extended interactions between the 
ARE and flanking sequences that were both 5' and 3' to the 
predicted AR-binding half-sites. One interpretation sug­
gested by these findings is that because of the degeneracy of 
the second half-site in the primary AR-binding motifs, ad­
ditional interactions were needed to stabilize AR-DNA 
complexes.
The presence of what appear to be overlapping half-sites 
within the AREs of the IGF-I gene is unique among AREs 
described thus far. There is one other example of an ARE 
having multiple AR-binding sites, which was identified in 
the human secretory component gene (17) and was found to 
consist of three contiguous (nonoverlapping) half-sites sim­
ilar to the SRE consensus sequence, with a fourth half-site 
located just downstream. This ARE is highly selective for AR 
over GR, perhaps in part as a consequence of the presence of 
multiple half-sites. Conversely, a glucocorticoid response 
element composed of multiple overlapping half-sites has 
been described in the Ast gene (15) and has been found to be 
highly selective for transcriptional activation by the GR over 
AR or other receptors with overlapping DNA-binding spec­
ificities (15).
It is attractive to propose, therefore, that the organization 
of IGF-I AREs as several overlapping half-sites contributes to 
the selectivity of these AREs for AR over GR. However, other 
features of these AREs may also contribute to selectivity for
transcriptional activation by AR over GR, including inter­
actions of DNA sequences outside the half-sites with amino 
acids within the second zinc finger or hinge domain (18) and 
interactions with other transcription factors (42). It is notable 
that for the AREs of the IGF-I gene, sequences flanking each 
ARE interacted with the AR, suggesting that such interac­
tions may contribute to discrimination by these AREs of AR 
and GR.
The IGF-I gene is an interesting example of a gene that is 
regulated in opposite directions by AR and GR. Whereas AR 
up-regulates IGF-I, GR represses it in cultured cells and 
reduces IGF-I protein levels in intact animals (43, 44). The 
relatively high degree of discrimination of ARE1 and ARE2 
for AR vs. GR appears to be one way in which the cell ensures 
that these opposite effects of AR and GR on IGF-I expression 
occur. An additional mechanism has also been described. 
Glucocorticoids have been shown to up-regulate the expres­
sion of C A AT /  enhancer binding protein 3, which then binds 
to downstream elements within the IGF-I promoter (43) and 
represses IGF-I transcription.
Thus, the human IGF-I gene contains two AREs localized 
between —1320 and —1420 bases upstream of the first codon, 
with each ARE organized as several overlapping half-sites 
and every half-site being paired with a degenerate half-site. 
Binding of these core motifs to the AR depends upon inter­
actions between the AR and flanking sequences. This com­
bination of degenerate core binding motif and interactions 
with flanking sequences confers selectivity for AR over GR 
that may be enhanced by additional downstream elements. 
The findings provide direct support for the view that an­
drogens stimulate IGF-I expression in tissues and provide a 
molecular mechanism by which such expression occurs. In­
creased expression of IGF-I induced by androgens may con­
tribute to many of the anabolic and growth-promoting effects 
of testosterone. Testosterone-induced IGF-I expression may 
also explain the beneficial, and apparently protective, effects 
of androgens in humans or animals exposed to glucocorti­
coids (45-48).
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